ClinicalTrials.gov term: Lymphoma, Mantle-Cell
Mantle Cell Lymphoma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
18 trials changed in the last 30 days: 0 stopped, 11 with notable changes, 7 with minor changes only.
- Notable: Auto Stem Cell Transplant for Lymphoma Patients Primary completion pushed from Sep 30, 2026 to Sep 30, 2027
- Notable: Zanubrutinib, Obinutuzumab, and Sonrotoclax · Mantle Cell Lymphoma Start date pushed from Sep 2026 to Dec 2026
- Minor: Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body · B-Cell Malignancies Trial arms changed: 4 → 1
- Notable: Acalabrutinib, Obinutuzumab, and Glofitamab · Relapsed or Refractory Mantle Cell Lymphoma Primary and study completion pushed from Oct 16, 2026 to Jul 13, 2027
- Minor: CAN3001 · PCI-32765 (Ibrutinib) Trial sites reduced: 175 → 156 locations
- Minor: Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib · Previously Untreated Mantle Cell Lymphoma Trial sites expanded: 238 → 242 locations
- Notable: Keynatinib Primary completion pushed from Oct 10, 2027 to Oct 10, 2032
- Notable: Ibrutinib and Pembrolizumab · Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Primary completion pushed from Nov 2025 to Apr 2027
- Minor: Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Trial sites reduced: 150 → 145 locations
- Notable: Soundtrack-E · AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Primary and study completion pushed from Jun 11, 2029 to May 20, 2030
- Notable: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide · Newly Diagnosed High Risk Mantle Cell Lymphoma Recruitment resumed after suspension
- Minor: Cellular Immunotherapy Following Chemotherapy · Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Start date pushed from Sep 24, 2014 to Oct 14, 2014
- Minor: Selinexor Plus Combination Chemotherapy · Advanced B Cell Non-Hodgkin Lymphoma Primary and study completion moved earlier from Dec 2027 to Jun 25, 2027
- Notable: Golcadomide in Combination With Rituximab · Relapsed or Refractory Mantle Cell Lymphoma Recruitment opened
- Notable: Treatment · B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader Sponsor changed: BeiGene to BeOne Medicines
- Notable: CLIC-2201 · Relapsed/Refractory B Cell Malignancies Primary completion pushed from Aug 1, 2026 to Aug 1, 2027
- Notable: CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Primary completion pushed from Jan 1, 2027 to Aug 1, 2027
- Minor: Acalabrutinib, Umbralisib, and Ublituximab · Previously Untreated Mantle Cell Lymphoma Study completion pushed from Jul 21, 2026 to Jul 13, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-02 | NCT07855016 A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody… | TransThera Sciences (Nanjing), Inc. new | Phase 2 |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 58 | |
| Phase 1/2 | 35 | |
| Phase 2 | 98 | |
| Phase 3 | 11 | |
| Phase 4 | 1 |
Not charted: 30 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
City of Hope Medical Center (18) · M.D. Anderson Cancer Center (16) · Ruijin Hospital (7) · BeOne Medicines (6) · AstraZeneca (5) · National Cancer Institute (NCI) (5) · Fondazione Italiana Linfomi - ETS (4) · Acerta Pharma BV (3) · Emory University (3) · Fred Hutchinson Cancer Center (3)
Get alerts when Mantle Cell Lymphoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.